ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
허셉틴 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 6.1%의 연평균 성장률로 95억 9,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 바이오시밀러의 확대, 표적 치료제의 채택 확대, 신흥 시장에서의 의료 접근성 향상, 진행 중인 암 분야 연구 개발, HER2 양성 암의 유병률 증가 등에 기인할 것으로 보입니다. 예측 기간 동안 주요 동향으로는 항체약물접합체 개발, 바이오시밀러 제제의 발전, 신약개발에 AI의 통합, 맞춤형 의료 접근법, 약물전달 시스템 개선 등을 꼽을 수 있습니다.
유방암 발병률 증가가 허셉틴 시장 확대를 견인할 것으로 예상됩니다. 유방의 세포에서 발생하는 유방암은 일반적으로 유관이나 소엽에서 시작되며, 침윤성 유관암(IDC), 침윤성 소엽암(ILC), HER2 양성 유방암 등의 유형이 있습니다. 유방암 환자의 증가는 음주량 증가, 식생활의 변화, 운동 부족 등의 생활습관이 한 요인으로 작용하고 있으며, 이 모든 것이 위험도 증가에 기여하고 있습니다. 특히 HER2 양성 유방암 진단을 받고 치료를 원하는 사람들이 늘어남에 따라 허셉틴과 같은 효과적인 분자 표적 치료제에 대한 수요는 계속 증가하고 있습니다. 예를 들어, 미국 암학회는 2025년 1월 미국 내 유방암 신규 환자 수는 약 31만 9,750명, 사망자 수는 4만 2,680명에 달할 것으로 예측하고 있습니다. 따라서 유방암 발병률의 증가는 허셉틴 시장의 성장에 박차를 가하고 있습니다.
허셉틴 시장의 주요 기업들은 환자 접근성을 개선하고 HER2 양성 암의 치료 결과를 개선하기 위해 혁신적인 바이오시밀러 제품을 개발하고 있습니다. 바이오시밀러는 승인된 생물학적 제제의 고도로 유사한 버전으로, 동등한 안전성, 유효성 및 품질을 보장하기 위해 첨단 생명공학 기술을 활용하여 개발됩니다. 예를 들어, 미국 제약사 Accord BioPharma Inc.는 2024년 4월 HER2 과발현 유방암 및 위암 치료제로 허셉틴의 바이오시밀러인 HERCESSI(trastuzumab-strf)를 미국 식품의약국(FDA)으로부터 승인받았습니다. HERCESSI와 같은 바이오시밀러는 오리지널 생물학적 제제와 동등한 효능과 안전성을 유지하면서 환자에게 비용 효율적인 치료 옵션을 제공합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 허셉틴 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 허셉틴 시장 : 성장률 분석
세계의 허셉틴 시장 실적 : 규모와 성장, 2019-2024년
세계의 허셉틴 시장 예측 : 규모와 성장, 2024-2029년, 2034년
세계의 허셉틴 전체 시장(TAM)
제6장 시장 세분화
세계의 허셉틴 시장 : 제품별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
생물학적 제제
바이오시밀러
세계의 허셉틴 시장 : 용도별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
유방암
위암
세계의 허셉틴 시장 : 지불자별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
상업용 및 개인용
공공
세계의 허셉틴 시장 : 유통 채널별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
병원 약국
전문 약국
세계의 허셉틴 시장, 생물학적 제제 종류별 하위 세분화, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
정맥내(IV) 생물학적 제제
피하(SC) 생물학적 제제
세계의 허셉틴 시장, 바이오시밀러 종류별 하위 세분화, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
정맥내(IV) 바이오시밀러
피하(SC) 바이오시밀러
제7장 지역별·국가별 분석
세계의 허셉틴 시장 : 지역별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 허셉틴 시장 : 국가별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
허셉틴 시장 : 경쟁 구도
허셉틴 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Viatris Inc.
Teva Pharmaceutical Industries Ltd
Boehringer Ingelheim GmbH
Genentech Inc.
Dr. Reddy's Laboratories
Celltrion Healthcare
Mundipharma
Biocon Limited
Bio-Techne Corporation
Samsung Bioepis Co Ltd
AryoGen Pharmed
InvivoGen
Abnova Corporation
Shanghai Henlius Biotech Inc
Prestige Biopharma Pte Ltd.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
허셉틴 시장 2029년 : 새로운 기회를 제공하는 국가
허셉틴 시장 2029년 : 새로운 기회를 제공하는 부문
허셉틴 시장 2029년 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
ksm
영문 목차
영문목차
Herceptin, also known as trastuzumab, is a monoclonal antibody used to treat HER2-positive breast and gastric cancers. It specifically targets the HER2/neu receptor, which promotes the growth of cancer cells. By binding to this receptor, Herceptin inhibits tumor cell proliferation and marks them for destruction by the immune system.
The main products of Herceptin include biologics and biosimilars. Biologics are complex, large-molecule drugs derived from living organisms, used to treat various diseases, including cancer. The key payers include commercial, private, and public sectors, with applications in the treatment of breast and gastric cancers. Treatment is distributed through various channels, such as hospital pharmacies and specialty pharmacies.
The herceptin market research report is one of a series of new reports from The Business Research Company that provides herceptin market statistics, including herceptin industry global market size, regional shares, competitors with a herceptin market share, detailed herceptin market segments, market trends and opportunities, and any further data you may need to thrive in the herceptin industry. The herceptin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The herceptin market size has grown strongly in recent years. It will grow from$7.10 billion in 2024 to $7.55 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth during the historic period can be attributed to regulatory approvals, the rising incidence of breast cancer, advancements in monoclonal antibody technology, positive clinical trial outcomes, and increasing healthcare expenditure.
The herceptin market size is expected to see strong growth in the next few years. It will grow to$9.59 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth during the forecast period can be attributed to the expansion of biosimilars, increasing adoption of targeted therapies, improved healthcare access in emerging markets, ongoing research and development in oncology, and the rising prevalence of HER2-positive cancers. Key trends in the forecast period include the development of antibody-drug conjugates, advancements in biosimilar formulations, the integration of AI in drug discovery, personalized medicine approaches, and improvements in drug delivery systems.
The growing incidence of breast cancer is expected to drive the expansion of the Herceptin market. Breast cancer, which develops in the cells of the breast, typically starts in the milk ducts or lobules, and includes types such as invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), and HER2-positive breast cancer. The rise in breast cancer cases is partly attributed to lifestyle factors such as higher alcohol consumption, poor diet, and a lack of physical activity, all of which contribute to a higher risk. As more individuals, particularly those diagnosed with HER2-positive breast cancer, are seeking treatment, the demand for effective targeted therapies such as Herceptin continues to grow. For instance, in January 2025, the American Cancer Society projected approximately 319,750 new cases of breast cancer in the U.S. with 42,680 expected deaths. Therefore, the increasing incidence of breast cancer is fueling the growth of the Herceptin market.
Leading companies in the Herceptin market are developing innovative biosimilar products to improve patient access and enhance therapeutic outcomes for HER2-positive cancers. Biosimilars are highly similar versions of approved biologic drugs, developed using advanced biotechnology to ensure comparable safety, efficacy, and quality. For example, in April 2024, Accord BioPharma Inc., a U.S.-based pharmaceutical company, received approval from the U.S. Food and Drug Administration for HERCESSI (trastuzumab-strf), a biosimilar to Herceptin, for the treatment of HER2-overexpressing breast and gastric cancers. Biosimilars such as HERCESSI provide patients with a cost-effective treatment option while maintaining comparable efficacy and safety to the original biologic drug.
In December 2022, Celltrion Inc., a South Korea-based biopharmaceutical company, merged with Celltrion Healthcare Co. to enhance its cost competitiveness and diversify its product pipeline. This merger is designed to streamline operations, boost research investments, and simplify the company's structure. Celltrion Healthcare Co., known for developing the Herceptin biosimilar Herzuma (trastuzumab-pkrb), which was approved by the FDA, is now positioned to further strengthen its global biopharma presence following this strategic merger.
Major players in the herceptin market are Pfizer Inc., Roche Holding AG, Merck & Co Inc., GlaxoSmithKline plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim GmbH, Genentech Inc., Dr. Reddy's Laboratories, Celltrion Healthcare, Mundipharma, Biocon Limited, Bio-Techne Corporation, Samsung Bioepis Co Ltd, AryoGen Pharmed, InvivoGen, Abnova Corporation, Shanghai Henlius Biotech Inc., and Prestige Biopharma Pte Ltd.
North America was the largest region in the herceptin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in herceptin report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the herceptin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The herceptin market consists of sales of trastuzumab, trastuzumab deruxtecan, and ado-trastuzumab emtansine. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Herceptin Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on herceptin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for herceptin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The herceptin market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Product: Biologic; Biosimilar
2) By Application: Breast Cancer; Gastric Cancer
3) By Payer: Commercial And Private; Public
4) By Distribution Channel: Hospital Pharmacy; Specialty Pharmacy
Subsegments:
1) By Biologic: Intravenous (IV) Biologics; Subcutaneous (SC) Biologic
2) By Biosimilar: Intravenous (IV) Biosimilars; Subcutaneous (SC) Biosimilars
Companies Mentioned: Pfizer Inc.; Roche Holding AG; Merck & Co Inc.; GlaxoSmithKline plc; Amgen Inc.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Herceptin Market Characteristics
3. Herceptin Market Trends And Strategies
4. Herceptin Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Herceptin Growth Analysis And Strategic Analysis Framework
5.1. Global Herceptin PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Herceptin Market Growth Rate Analysis
5.4. Global Herceptin Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Herceptin Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Herceptin Total Addressable Market (TAM)
6. Herceptin Market Segmentation
6.1. Global Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Biologic
Biosimilar
6.2. Global Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Breast Cancer
Stomach Or Gastric Cancer
6.3. Global Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Commercial And Private
Public
6.4. Global Herceptin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Specialty Pharmacy
6.5. Global Herceptin Market, Sub-Segmentation Of Biologic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intravenous (IV) Biologics
Subcutaneous (SC) Biologic
6.6. Global Herceptin Market, Sub-Segmentation Of Biosimilar, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intravenous (IV) Biosimilars
Subcutaneous (SC) Biosimilars
7. Herceptin Market Regional And Country Analysis
7.1. Global Herceptin Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Herceptin Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Herceptin Market
8.1. Asia-Pacific Herceptin Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Herceptin Market
9.1. China Herceptin Market Overview
9.2. China Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Herceptin Market
10.1. India Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Herceptin Market
11.1. Japan Herceptin Market Overview
11.2. Japan Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Herceptin Market
12.1. Australia Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Herceptin Market
13.1. Indonesia Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Herceptin Market
14.1. South Korea Herceptin Market Overview
14.2. South Korea Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Herceptin Market
15.1. Western Europe Herceptin Market Overview
15.2. Western Europe Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Herceptin Market
16.1. UK Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Herceptin Market
17.1. Germany Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Herceptin Market
18.1. France Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Herceptin Market
19.1. Italy Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Herceptin Market
20.1. Spain Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Herceptin Market
21.1. Eastern Europe Herceptin Market Overview
21.2. Eastern Europe Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Herceptin Market
22.1. Russia Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Herceptin Market
23.1. North America Herceptin Market Overview
23.2. North America Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Herceptin Market
24.1. USA Herceptin Market Overview
24.2. USA Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Herceptin Market
25.1. Canada Herceptin Market Overview
25.2. Canada Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Herceptin Market
26.1. South America Herceptin Market Overview
26.2. South America Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Herceptin Market
27.1. Brazil Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Herceptin Market
28.1. Middle East Herceptin Market Overview
28.2. Middle East Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Herceptin Market
29.1. Africa Herceptin Market Overview
29.2. Africa Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Herceptin Market Competitive Landscape And Company Profiles
30.1. Herceptin Market Competitive Landscape
30.2. Herceptin Market Company Profiles
30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
31. Herceptin Market Other Major And Innovative Companies
31.1. Viatris Inc.
31.2. Teva Pharmaceutical Industries Ltd
31.3. Boehringer Ingelheim GmbH
31.4. Genentech Inc.
31.5. Dr. Reddy's Laboratories
31.6. Celltrion Healthcare
31.7. Mundipharma
31.8. Biocon Limited
31.9. Bio-Techne Corporation
31.10. Samsung Bioepis Co Ltd
31.11. AryoGen Pharmed
31.12. InvivoGen
31.13. Abnova Corporation
31.14. Shanghai Henlius Biotech Inc
31.15. Prestige Biopharma Pte Ltd.
32. Global Herceptin Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Herceptin Market
34. Recent Developments In The Herceptin Market
35. Herceptin Market High Potential Countries, Segments and Strategies
35.1 Herceptin Market In 2029 - Countries Offering Most New Opportunities
35.2 Herceptin Market In 2029 - Segments Offering Most New Opportunities
